Royalty Pharma plc Class A Ordinary Shares
RPRXRoyalty Pharma plc (RPRX) is a pharmaceutical royalty financial company that acquires royalties from commercialized medicines, biotechnological innovations, and research and development programs. Established as a leading player in the royalty monetization sector, it provides capital to biopharmaceutical companies and researchers while generating revenue from the royalties it holds on successful drug sales.
Dividend History
Investors can expect a dividend payout of $0.22 per share, scheduled to be distributed in 2 days on December 10, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 10, 2025 | $0.22 | 2025-11-14 | 2025-11-14 |
| September 10, 2025 | $0.22 | 2025-08-15 | 2025-08-15 |
| June 10, 2025 | $0.22 | 2025-05-16 | 2025-05-16 |
| March 10, 2025 | $0.22 | 2025-02-21 | 2025-02-21 |
| December 10, 2024 | $0.21 | 2024-11-15 | 2024-11-15 |
Dividends Summary
- Royalty Pharma plc Class A Ordinary Shares has issued 22 dividend payments over the past 5 years
- The most recent dividend was paid 89 days ago, on September 10, 2025
- The highest dividend payed out to investors during this period was $0.22 per share
- The average dividend paid during this period was $0.19 per share.
Company News
Cytokinetics reported strong progress towards potential FDA approval of aficamten for hypertrophic cardiomyopathy by December 26, 2025, with ongoing regulatory reviews in the U.S., China, and E.U. The company maintains a strong cash position of $1.25 billion and continues advancing multiple cardiac muscle treatment programs.
Royalty Pharma will acquire a royalty interest in Amgen's Imdelltra, a first-in-class immunotherapy for extensive-stage small cell lung cancer, for $885 million upfront with an additional potential $65 million option from BeOne Medicines.
The article discusses three dividend-paying stocks - Royalty Pharma, W.P. Carey, and Omega Healthcare Investors - that have seen their stock prices fall recently but offer attractive dividend yields. The author believes these stocks could be good additions to a diversified portfolio.
Sector ETF report for IHE
